National Institute of Allergy and Infectious Diseases (NIAID): COVID-19 trials

The registry lists 57 COVID-19 studies with National Institute of Allergy and Infectious Diseases (NIAID) as lead sponsor. 5 are open to participants now and 35 have results posted.

Phase 1 11Phase 2 12Phase 3 17Phase 4 2No phase 16(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• A Safety, Reactogenicity and Immunogenicity Trial of RVX-sCPD9 Booster Intranasal COVID-19 VaccineNot yet recruitingNCT07703475Phase 1
• A Safety and Immunogenicity Trial of OCU500, ChAd36 Vector Encoding SARS-CoV-2 Spike Vaccine Via Intranasal and Inhalational Routes in Previously Vaccinated AdultsRecruitingNCT07536308Phase 1
• Respiratory Virus Sampling and RepositoryRecruitingNCT05266222
• Send-In Sample Collection for Comprehensive Analyses of Innate and Adaptive Immune Responses During Acute COVID-19 and ConvalescenceRecruitingNCT04582903
• Viral Infections in Healthy and Immunocompromised HostsRecruitingNCT01306084
• Phase 1 Study on Bioavailability, Food Effect, and Drug-Drug Interaction of ALG-097558 Tablets in Healthy VolunteersCompletedNCT06945276Phase 1Results posted
• Aviptadil for Severely Ill Inpatients With COVID-19 (An ACTIV-3b/TESICO Treatment Trial)CompletedNCT06729606Phase 3Results posted
• Remdesivir for Severely Ill Inpatients With COVID-19 (An ACTIV-3b/TESICO Treatment Trial)CompletedNCT06729593Phase 3Results posted
• Safety Study of SLV213 for the Treatment of COVID-19.TerminatedNCT06146374Phase 1Results posted
• PF-07304814 for Inpatients With COVID-19 (An ACTIV-3/TICO Treatment Trial)TerminatedNCT05780541Phase 3Results posted
• MP0420 for Inpatients With COVID-19 (An ACTIV-3/TICO Treatment Trial)CompletedNCT05780463Phase 3Results posted
• AZD7442 for Inpatients With COVID-19 (An ACTIV-3/TICO Treatment Trial)CompletedNCT05780437Phase 3Results posted
• BRII-196/BRII-198 for Inpatients With COVID-19 (An ACTIV-3/TICO Treatment Trial)CompletedNCT05780424Phase 3Results posted
• VIR-7831 for Inpatients With COVID-19 (An ACTIV-3/TICO Treatment Trial)CompletedNCT05780281Phase 3Results posted
• LY3819253 (LY-CoV555) for Inpatients With COVID-19 (An ACTIV-3/TICO Treatment Trial)CompletedNCT05780268Phase 3Results posted
• COVID Protection After Transplant - Sanofi GSK (CPAT-SG) StudyCompletedNCT05518487Phase 2Results posted
• COVID-19 Variant Immunologic Landscape Trial (COVAIL Trial)CompletedNCT05289037Phase 2Results posted
• COVID Protection After Transplant-Immunosuppression ReductionCompletedNCT05077254Phase 2Results posted
• COVID-19 Booster Vaccine in Autoimmune Disease Non-RespondersTerminatedNCT05000216Phase 2Results posted
• ACTIV-5 / Big Effect Trial (BET-C) for the Treatment of COVID-19CompletedNCT04988035Phase 2Results posted
• The Safety of Administering a Second Dose of a COVID-19 mRNA Vaccine in Individuals Who Experienced a Systemic Allergic Reaction to an Initial DoseCompletedNCT04977479Phase 2Results posted
• Vaccination for Recovered Inpatients With COVID-19 (VATICO)CompletedNCT04969250Phase 4Results posted
• SARS-CoV-2 Immune Responses After COVID-19 Therapy and Subsequent VaccineCompletedNCT04952402Phase 4Results posted
• ACTIV-3b: Therapeutics for Severely Ill Inpatients With COVID-19CompletedNCT04843761Phase 3Results posted
• A Study of SARS CoV-2 Infection and Potential Transmission in Individuals Immunized With Moderna COVID-19 VaccineCompletedNCT04811664Phase 3Results posted
• Safety and Immunogenicity Study of a SARS-CoV-2 (COVID-19) Variant Vaccine (mRNA-1273.351) in Naïve and Previously Vaccinated AdultsCompletedNCT04785144Phase 1Results posted
• COVID19 SARS Vaccinations: Systemic Allergic Reactions to SARS-CoV-2 VaccinationsCompletedNCT04761822Phase 2Results posted
• Adaptive COVID-19 Treatment Trial 4 (ACTT-4)CompletedNCT04640168Phase 3Results posted
• ACTIV-5 / Big Effect Trial (BET-B) for the Treatment of COVID-19CompletedNCT04583969Phase 2Results posted
• ACTIV-5 / Big Effect Trial (BET-A) for the Treatment of COVID-19CompletedNCT04583956Phase 2Results posted
• PK and Safety of Remdesivir for Treatment of COVID-19 in Pregnant and Non-Pregnant Women in the USCompletedNCT04582266Results posted
• ACTIV-2: A Study for Outpatients With COVID-19CompletedNCT04518410Phase 2/3Results posted
• Adaptive COVID-19 Treatment Trial 3 (ACTT-3)CompletedNCT04492475Phase 3Results posted
• Adaptive COVID-19 Treatment Trial 2 (ACTT-2)CompletedNCT04401579Phase 3Results posted
• COVID-19 and Anti-CD14 Treatment TrialTerminatedNCT04391309Phase 2Results posted
• COVID-19: Human Epidemiology and Response to SARS-CoV-2CompletedNCT04375761Results posted
• Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19TerminatedNCT04358068Phase 2Results posted
• Safety and Immunogenicity Study of 2019-nCoV Vaccine (mRNA-1273) for Prophylaxis of SARS-CoV-2 Infection (COVID-19)CompletedNCT04283461Phase 1Results posted
• Adaptive COVID-19 Treatment Trial (ACTT)CompletedNCT04280705Phase 3Results posted
• Evaluating the Use of Pitavastatin to Reduce the Risk of Cardiovascular Disease in HIV-Infected AdultsCompletedNCT02344290Phase 3Results posted
• A Safety and Immunogenicity Trial of Boost-2867 Vaccine, Via Intranasal and Intramuscular RoutesActive, not recruitingNCT07221162Phase 1
• Safety and Immunogenicity Trial of PepGNP-COVID19 Vaccine in AdultsActive, not recruitingNCT07183709Phase 1
• Safety, Reactogenicity, and Immunogenicity Trial of STX-S SARS-CoV-2 Vaccine in AdultsCompletedNCT07095231Phase 1
• Safety and Immunogenicity Trial of MPV/S-2P SARS-CoV-2 Vaccine in AdultsCompletedNCT06441968Phase 1
• Phase I Safety Study of B/HPIV3/S-6P Vaccine Via Nasal Spray in AdultsCompletedNCT06026514Phase 1
• International Study on COVID-19 Vaccine to Assess Immunogenicity, Reactogenicity and Efficacy (InVITE)CompletedNCT05096091
• Vaccine Responses to SARS-CoV-2 and Other Emerging Infectious DiseasesActive, not recruitingNCT05078905
• The Effect of Helminth Infection Plus COVID-19 Infection on the Immune Response and Intestinal MicroorganismsActive, not recruitingNCT04813328
• Natural History of Systemic and Nasal Mucosal Immunity to Influenza and SARS-CoV-2 in Adults After VaccinationCompletedNCT04794829
• COVID-19: Pediatric Research Immune Network on SARS-CoV-2 and MIS-CCompletedNCT04588363
• ACTIV-3: Therapeutics for Inpatients With COVID-19CompletedNCT04501978Phase 3
• A Longitudinal Study of COVID-19 Sequelae and ImmunityActive, not recruitingNCT04411147
• COVID-19 Associated Lymphopenia Pathogenesis Study in BloodCompletedNCT04401436
• Pathogenesis of BTK-mediated Hyper-Inflammatory Responses in COVID-19 (RESPOND)WithdrawnNCT04394884
• Surveillance of Individuals Following SARS-CoV-2 InfectionCompletedNCT04383444
• Immunophenotyping Assessment in a COVID-19 CohortCompletedNCT04378777
• Collection of Anti-SARS-CoV-2 Immune PlasmaCompletedNCT04344977